Nebraska Clinical Trials Report — July 2026

Nebraska residents considering a clinical trial should act promptly if they match a study expected to close within the next 90 days. The state has 30 trials approaching enrollment closure, including 6 that accept healthy volunteers. Prostate cancer is the most common focus among these time-sensitive studies, followed by endometrial cancer, prostatic neoplasms, atopic dermatitis, and asthma.

Nebraska currently has 717 recruiting trials across 21 cities and 384 research sites. Twelve new trials opened in July, down from 17 in May and matching the recent slowdown after June’s 17 new studies. People who need screening, testing, or treatment should begin inquiries early because projected closing dates can change and eligibility reviews may take time.

Closing studies create a narrow window for action

Cancer-related studies make up much of the closing-soon group. Four trials involve prostate cancer, while two each address endometrial cancer, prostatic neoplasms, atopic dermatitis, and asthma. Other conditions represented include acute myeloid leukemia with mutated NPM1, acute myeloid leukemia, acute respiratory distress syndrome, advanced solid tumors, and amniotic band syndrome.

• Prostate cancer — 4 closing-soon trials
• Endometrial cancer and prostatic neoplasms — 2 each
• Atopic dermatitis and asthma — 2 each
• AML with mutated NPM1, AML, acute respiratory distress syndrome, advanced solid tumor, and amniotic band syndrome — 1 each

Six of the 30 studies nearing closure accept healthy volunteers. That opportunity is smaller than Nebraska’s broader pool of 73 recruiting healthy-volunteer studies, so healthy adults should check requirements now rather than waiting for a later month. Enrollment status, age ranges, medical history rules, compensation, travel expectations, and screening procedures vary by study.

July brings major Phase 2 and Phase 3 drug research

New-trial activity in July centered on cancer, respiratory disease, immune conditions, and healthy-adult vaccination research. Ten of the 12 new studies were industry-sponsored, while two were classified as other. Six involved drugs, three involved biological interventions, two involved devices, one was behavioral, and one fell into another category.

Several new studies stand out because of their phase, planned enrollment, or sponsor. Sanofi opened a large Phase 1/2 vaccine study for adults age 60 and older. AstraZeneca and Bristol-Myers Squibb each opened notable late-stage oncology studies, while Nektar Therapeutics launched a Phase 3 atopic dermatitis trial.

• NCT07734649 — Sanofi’s Phase 1/2 study of an RSV and human metapneumovirus vaccine candidate in approximately 2,400 adults age 60 and older. The randomized, placebo-controlled study will evaluate immune response and safety.
• NCT07720284 — AstraZeneca’s Phase 3 study of Dato-DXd plus rilvegostomig versus standard care for high-risk muscle-invasive urothelial carcinoma. The study plans to enroll 915 adults and evaluates adjuvant treatment after radical resection.
• NCT07680790 — Bristol-Myers Squibb’s Phase 3 IZABRIGHT-Lung02 study, enrolling 850 people with previously untreated, locally advanced or metastatic EGFR-mutant non-small cell lung cancer.
• NCT07690371 — Nektar Therapeutics’ Phase 3 study of rezpegaldesleukin for people age 12 and older with moderate-to-severe atopic dermatitis, with planned enrollment of 510.
• NCT07680764 — Bristol-Myers Squibb’s Phase 2 study of imzokitug in combination with pumitamig and platinum-doublet chemotherapy for first-line treatment of locally advanced or metastatic NSCLC, enrolling 160 participants.
• NCT07682896 — A Phase 2 evaluation of YB-101 for safety, tolerability, pharmacokinetics, and efficacy in Graves’ disease, with 232 planned participants.

The new-trial list also includes studies for bladder or urothelial cancer, clear cell renal cell carcinoma, COPD, and metastatic NSCLC. This gives patients with several serious or chronic conditions new options to investigate, particularly those who may qualify for studies testing combinations of immunotherapy, targeted therapy, chemotherapy, or other biological treatments.

Healthy adults and older Nebraskans have new opportunities

Two of the 12 new trials accept healthy volunteers, and one new study specifically focuses on healthy adults. The most prominent opportunity is NCT07734649, which is designed for adults age 60 and older and examines vaccination against RSV and human metapneumovirus. Its multi-center design and planned enrollment of 2,400 participants make it one of the largest new studies in the state’s July pipeline, although local site availability and screening requirements must be confirmed.

Older adults are included in the eligibility criteria for 12 new trials. One new trial includes children, while no new trials are limited exclusively to women or men. Adults who do not have a diagnosed condition should review both healthy-volunteer studies and vaccine or prevention studies, since eligibility may depend on age, prior exposure, medications, vaccination history, and general health.

Monthly new-trial activity has fluctuated during 2026: 15 studies opened in February, 18 in March, 18 in April, 9 in May, 17 in June, and 12 in July. The trend suggests that the number of openings can change considerably from month to month. People who do not find a match this month may see different options emerge later, but those who fit a closing study face a more immediate deadline.

Omaha dominates new openings, with options in two other cities

New research remains concentrated in Omaha, Nebraska’s leading clinical-trial center. Omaha recorded 10 of July’s new trials. Grand Island and Lincoln each recorded 2, giving residents outside the Omaha area some local options while showing that most newly opened studies are clustered in the state’s largest research hub.

• Omaha — 10 new trials
• Grand Island — 2
• Lincoln — 2

The broader network of 717 recruiting trials spans 21 cities and 384 sites, so July’s concentration does not mean all statewide opportunities are limited to Omaha. However, people in smaller communities may need to discuss travel, visit frequency, and whether some assessments can occur remotely. A trial with a national enrollment target may have only one Nebraska location, making local site confirmation essential.

Who should contact research sites now?

Patients with prostate cancer, endometrial cancer, urothelial cancer, NSCLC, atopic dermatitis, asthma, Graves’ disease, or other conditions represented in the new and closing studies should review eligibility immediately. Healthy adults—especially those age 60 and older—also have reason to act, with 73 healthy-volunteer studies recruiting statewide and six closing within 90 days.

People can begin by checking the NCT number and contacting the listed research site to ask whether enrollment is still open in Nebraska. A site coordinator can explain the screening process, required records, visit schedule, possible risks, and whether participation involves an investigational drug, vaccine, device, or behavioral intervention.

As summer progresses, Nebraska’s research landscape is likely to keep shifting: some enrollment windows will close, while additional oncology, respiratory, immune, and healthy-volunteer studies may open in Omaha, Lincoln, Grand Island, and other communities across the state.